Case 2:05-cv-06609-JP Document 51 Filed 05/24/10 Page 1 of 97 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA UNITED STATES OF AMERICA and the States of ARKANSAS,…

Slide 1EBM Chengyu (Cheryl) Xu March, 2012 ACS trials Slide 2 Outline – over 70 ACS trials Mangement strategy Cardiogenic shock Lytics/Referfusion Stable CAD/Elective PCI…

Slide 1Coagulation Testing What is it? Why do we need it POC? ITC Educational Services, Edison, NJ Marcia L. Zucker, Ph.D. Director of Clinical Research Slide 2 Coagulation…

Slide 1Coagulation Testing What is it? Why do we need it POC? Marcia L. Zucker, Ph.D. Director of Clinical Research Educational Services, Edison, NJ Slide 2 Coagulation Testing…

Slide 1 Slide 2 Latest Developments in the Treatment of Invasive Aspergillosis William J. Steinbach, MD Assistant Professor of Pediatrics, Molecular Genetics, and Microbiology…

Slide 1Pharmacology for Anesthesia I Introduction Slide 2 What is a Drug? Slide 3 Slide 4 Pharmacokinetics (PK) What the body does to the drug Absorption Distribution Metabolism…

1. IDSA GUIDELINESClinical Practice Guidelines for the Managementof Candidiasis: 2009 Update by the InfectiousDiseases Society of AmericaPeter G. Pappas,1 Carol A. Kauffman,2…

1. Regulatory and Scientific Impact of FDAMA Joseph F. Holson, Ph.D. WIL Research Laboratories, Inc. 2. The ‘carrot’ and the ‘stick’ FDAMA of 1997: • law • optional…

Anti-Fouling/Non-Fouling Surfaces Anti-Fouling/Non-Fouling Surfaces BT5011-July-Dec-2014 1 BT5011-July-Dec-2014 2 When is the non-specific adsoption undesirable? BT5011-July-Dec-2014…

1. PEMBROLIZUMAB “Treatment of melanoma has never been this promising” By: Patwant Dhillon 2. METASTATIC MELANOMA •  10-year survival rate less than 10% •  Single-agent…